# Sakar Healthcare share price today (Sakar Healthcare Ltd, NSE: SAKAR) > Sakar Healthcare share price today: ₹1,009.70 at the NSE close on 18 November 2026, up 171.1% in a year. Sakar Healthcare (NSE: SAKAR) is worth ₹2,247 crore, trades at a P/E of 52.4 and has closed between ₹372.40 and ₹1,179.80 over the past 52 weeks. > Sakar Healthcare Ltd's share price has risen faster than its earnings: +171.1% in a year, against +71.9% for earnings per share. SAKAR · Hospitals · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/sakar-healthcare-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Mixed, from the last 12 quarters - Price: ₹1,009.70 (+171.1% in a year) - P/E: 52.4× (higher than 65% of the last 5.4 years) - Revenue (Sep 2026): ₹87.0 Cr (+50.0% on a year ago) - Profit (Sep 2026): ₹11.0 Cr (+120.0% on a year ago) - Operating margin: 27.6% (+8.6 points on a year ago) - ROCE: 12%, FY26 - ROIC: 11.9%, against a 12.0% cost of capital: −0.1 points The main question: the share price moved +171.1% in a year while yearly earnings per share moved +71.9%. The difference came from the market paying a higher multiple. ## What is the Sakar Healthcare share price today? Sakar Healthcare Ltd's share price was ₹1,009.70 at the close on 18 November 2026. It has been rising for 75 weeks. That is 24.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹372 and ₹1,180, and at that close it sat 79% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running. Over the last 9.8 years the share price moved +1,611% while the NIFTY 500 moved +230%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 13 November 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sakar Healthcare this quarter? Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), number of shareholders up 158% in a year and operating margin up 8 points on a year earlier. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹87 crore, +50% on a year earlier. Why: Revenue rose because cancer drug sales grew to about half the business and exports through partners and directly picked up. Next results: check whether revenue reaches the roughly ₹100 crore quarter management expected. From the earnings call on 27 Oct 2026. 2. Number of shareholders up 158% in a year 19,539 shareholders in the September 2026 quarter, against 7,565 a year earlier. 3. Operating margin up 8 points on a year earlier 28% in the September 2026 quarter, from 20%. Why: Margins rose because cancer drugs now make up a bigger part of sales and earn more than the older products. Next results: check whether the margin stays near 30% as cancer drugs become a bigger share of sales. From the earnings call on 27 Oct 2026. ## What are Sakar Healthcare's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Sakar Healthcare reported revenue of ₹87.0 crore, up 50.0% from ₹58.0 crore a year earlier, and a profit of ₹11.0 crore, up 120.0% from ₹5.00 crore. ### Sakar Healthcare results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹87.0 crore | ₹58.0 crore | +50.0% | | Profit | ₹11.0 crore | ₹5.00 crore | +120.0% | | Earnings per share | ₹5.08 | ₹2.04 | +149.0% | | Operating margin | 27.6% | 19.0% | +8.6 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Sakar Healthcare's management discussed these results on a call held on 27 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Sakar Healthcare share price history? Sakar Healthcare closed at ₹1,009.70 on 18 November 2026, up 171.1% from ₹372.40 a year earlier (21 November 2025) and up 567.3% over five years. Its highest weekly close since January 2017 was ₹1,179.80 on 18 September 2026. ### Sakar Healthcare share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹1,075.70 | −6.1% | | 1 month ago · 19 Oct 2026 | ₹923.20 | +9.4% | | 6 months ago · 15 May 2026 | ₹696.70 | +44.9% | | 1 year ago · 21 Nov 2025 | ₹372.40 | +171.1% | | 3 years ago · 17 Nov 2023 | ₹384.85 | +162.4% | | 5 years ago · 18 Nov 2021 | ₹151.30 | +567.3% | | Earliest weekly close in our records · 17 Jan 2017 | ₹59.00 | +1,611.4% | | Highest weekly close since January 2017, also the 52-week high · 18 Sep 2026 | ₹1,179.80 | −14.4% | | Lowest weekly close since January 2017 · 6 Sep 2019 | ₹46.95 | +2,050.6% | | 52-week low (weekly close) · 21 Nov 2025 | ₹372.40 | +171.1% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (516 weekly closes from 17 January 2017 to 18 November 2026.) ## What is the latest news on Sakar Healthcare? 18 Nov 2026: Sakar Healthcare closed at ₹1,009.70, down 6.1% on the week and up 9.4% on the month. 27 Oct 2026: Sakar Healthcare held its results call for July to September 2026. Management guided: Total revenue growth 35%+ this year and next, Q3 total at ~100Cr quarter. ### Earlier - Results for July to September 2026: Revenue up 50.0% and profit up 120.0% on a year earlier. ## What dividend does Sakar Healthcare pay? Sakar Healthcare has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Sakar Healthcare Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Sakar Healthcare management say on the latest results call? On the call for July to September 2026, held on 27 October 2026, Sakar Healthcare's management guided: Total revenue growth 35%+ this year and next, Q3 total at ~100Cr quarter. > “Therefore, we expect that we can take around 100 crores as an average figure to look forward to from this portfolio.” > Bikramjit Ghosh, on the call for July to September 2026 ### What management guided - FY28 oncology ~300Cr, mix crossing 50% next year to 60% in 2-3 years; partnerships to cross 70 this year. - Blended operating profit around 30% near term rising above 35% in ~2 years on full API integration. - Own-registration exports 20-25Cr in FY28 then 60-70Cr following year as mid-next-year grants contribute full year. - Accord portfolio average ~100Cr within 50-150Cr range over next ~2 years on proximity and supply-chain edge. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/27994-27-Oct-2026.pdf). (From the call for July to September 2026, 27 October 2026.) ## What to watch in Sakar Healthcare's next results? When Sakar Healthcare reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Q3 total at the flagged quarterly level - check print against management expectation for next quarter. Management raised each of these on the latest results call. - Q3 total at the flagged quarterly level - check print against management expectation for next quarter. - EU-GMP certificate issuance - check grant against holiday-adjusted timeline cited on call for continuity of commercial ramp. - Pending licensed and site-variation lots starting contribution plus first own authorization supplies - check dispatch and tender conversion. ## Which stock lists is Sakar Healthcare on? Sakar Healthcare is on one of our India lists: Momentum stocks. [Momentum stocks Market value: ₹2,309 crore](https://www.sectoralpha.in/momentum-stocks-india) ## Is Sakar Healthcare profitable? Sakar Healthcare Ltd earned ₹11.0 Cr of net profit in the Sep 2026 quarter, +120.0% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹30.0 Cr. Over 10 years profit has grown 31.1% a year on average. The same quarter a year earlier earned ₹5.0 Cr. The Sep 2026 quarter's profit is 12.6% of that quarter's revenue. For the full year, FY26 profit was ₹30.0 Cr (+66.7% on the year before). Why profit moved: revenue changed +50.0% on a year earlier and the margin moved +8.6 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +100.8% and revenue +48.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Sakar Healthcare make, and is it growing? Sakar Healthcare Ltd reported ₹87.0 Cr of revenue in the Sep 2026 quarter, +50.0% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 19.9% a year on average. The last full year, FY26, came in at ₹251 Cr. The last four reported quarters add to ₹301 Cr. FY26 revenue was ₹251 Cr, +41.0% on the year before. Recent pace: the last four quarters grew +48.1% on average, against 19.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +47.5%, against +35.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +100.0%, against +87.1% a year (accelerating). ## How much of every ₹100 of sales does Sakar Healthcare keep? Sakar Healthcare Ltd's operating margin was 27.6% in the Sep 2026 quarter, 8.6 percentage points higher than the same quarter a year ago. Across 13 years it has been between 19.5% and 28.1%. The latest quarter is within that range. Why the margin moved: operating margin changed +8.1 percentage points on the year while gross margin changed +0.5 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Sakar Healthcare's profit turning into cash? Over the last 3 years, 178% of Sakar Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹49.0 Cr of operating cash against ₹30.0 Cr of profit. After ₹28.0 Cr of spending on assets, ₹21.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 178% of profit came in as cash: the cash cycle got 108 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.9× depreciation over three years. The next section checks what that spending is building. ## Where does Sakar Healthcare's cash go? Sakar Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 127 days in FY26, up from 19 days in FY21. It spent ₹120 Cr on assets over the last 3 years. Customers take 73 days to pay, and stock sits for 207 days on average. At FY26 sales of ₹251 Cr, each day of that cycle ties up about ₹0.7 Cr, so roughly ₹87.0 Cr is tied up in the business at any time. FY26: customers took 73 days to pay and stock sat for 207 days, about 6.8 months of sales sitting as stock, for a full cycle of 127 days, longer than FY21's 19. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 207 days. Customers pay about 73 days after that. Suppliers are paid at 153 days. Together that makes the 127-day cycle. Spending on assets: ₹120 Cr over the last 3 years, against ₹63.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹4.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Sakar Healthcare's P/E ratio, and how does it compare with its own history? Sakar Healthcare Ltd's P/E is 52.4×, in the middle of its own history: higher than 65% of past readings. Its usual P/E (the middle reading) is 42.7×, over 5.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +71.9% while the price moved +171.1%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +46.2% a year; about +27.9% a year came from earnings growth and about +18.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Sakar Healthcare business getting better or worse? Sakar Healthcare Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 17.9% (four quarters to Sep 2026); each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Sakar Healthcare earn on its capital? Sakar Healthcare Ltd earned a ROCE of 12% in FY26. That is up from a low of 7% in FY24. Its return on capital used (ROIC) is 0.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 12.0% net margin and 0.52× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.0% net margin × 0.52× asset turnover × 1.48× leverage (assets divided by equity) ≈ 9.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 11.9% − 12.0% = −0.1 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 11.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 9.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Sakar Healthcare have too much debt? Sakar Healthcare Ltd has total debt of ₹46.0 Cr against shareholder equity of ₹346 Cr as of Sep 2026, so its debt is 0.13× its equity, which is very little. Year by year, that ratio went from 0.73 in FY22 to 0.22 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Sakar Healthcare shareholding pattern? Promoters cut their stake in Sakar Healthcare Ltd by 1.4 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 51.7% of the company. Domestic institutions moved +1.3 points over the same period, to 11.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −1.4 points over 8 quarters, to 51.7%; Domestic institutions: +1.3 points over 8 quarters, to 11.9%; Foreign institutions: −1.1 points over 8 quarters, to 12.3%. Why the owners changed: promoters drove it (−1.4 points), with the other side taken by domestic institutions (+1.3 points). They reduced their stake. ## How far is Sakar Healthcare from balance-sheet trouble? For Sakar Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sakar Healthcare rank in its industry? 67.3 out of 100, rank 5 of 20 in Hospitals, with 90% of the evidence available. Sakar Healthcare Ltd scores 67.3 out of 100 against the 20 companies it is compared with in Hospitals, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 32.1 + 11.1 + 8.9 + 15.2 = 67.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sakar Healthcare compared with? Sakar Healthcare ranks 5 of 20 Hospitals companies on the 4-Factor Sector Score, with 67.3 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Most evidence points up · 75% evidence 74.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 32.2% · Profit 93.8% · Operating margin change 2 points · 100% evidence Capital efficiency 22.6/25 · ROCE 26.2% (year to Mar 2026) · Operating margin 30.1% · 100% evidence Valuation 8.4/20 · P/E 52.6× · PEG n/a · 50% evidence Relative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 46.9% · 1 year 154.7% · 25% evidence · 7 of 7 weeks ahead Exact sum: 31 + 22.6 + 8.4 + 12.5 = 74.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · leader · Most evidence points up · 90% evidence 69.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.1/35 · Revenue 16.7% · Profit 19.6% · Operating margin change 2 points · 100% evidence Capital efficiency 20.4/25 · ROCE 22.6% (year to Mar 2026) · Operating margin 29% · 100% evidence Valuation 9.2/20 · P/E 25.9× · PEG n/a · 50% evidence Relative strength 16.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 9% · Strength vs NIFTY 500 (same reading) 10.7% · 1 year 8.4% · 100% evidence · 6 of 12 weeks ahead Exact sum: 23.1 + 20.4 + 9.2 + 16.4 = 69.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · quiet · Most evidence points up · 100% evidence 67.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 19.4% · Profit 35.2% · Operating margin change 1 points · 100% evidence Capital efficiency 16.8/25 · ROCE 17.4% (year to Mar 2026) · Operating margin 15.6% · 100% evidence Valuation 11.9/20 · P/E 56.6× · PEG 2.19 · 100% evidence Relative strength 11.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 1.5% · Strength vs NIFTY 500 (same reading) 2.9% · 1 year 19.3% · 100% evidence · 2 of 12 weeks ahead Exact sum: 27.5 + 16.8 + 11.9 + 11.4 = 67.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Most evidence points up · 75% evidence 67.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.2/35 · Revenue 18.4% · Profit 18.2% · Operating margin change 1 points · 100% evidence Capital efficiency 20.5/25 · ROCE 19.9% (year to Mar 2026) · Operating margin 19.9% · 100% evidence Valuation 14.7/20 · P/E 21.2× · PEG n/a · 50% evidence Relative strength 9.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -2.3% · 1 year -6.5% · 25% evidence · 3 of 12 weeks ahead Exact sum: 23.2 + 20.5 + 14.7 + 9.2 = 67.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. Sakar Healthcare Ltd this page SAKAR · leader · Most evidence points up · 90% evidence 67.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.1/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.1/25 · ROCE 12.4% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 8.9/20 · P/E 52.4× · PEG n/a · 50% evidence Relative strength 15.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 42.7% · Strength vs NIFTY 500 (same reading) 42.7% · 1 year 171.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.1 + 11.1 + 8.9 + 15.2 = 67.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · turning · Most evidence points up · 100% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 26.2% · Profit 9.3% · Operating margin change 4 points · 100% evidence Capital efficiency 18.7/25 · ROCE 17.4% (year to Mar 2026) · Operating margin 25.2% · 100% evidence Valuation 9.1/20 · P/E 62.4× · PEG 2.39 · 100% evidence Relative strength 16.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.8% · Strength vs NIFTY 500 (same reading) 13.2% · 1 year 17.1% · 100% evidence · 6 of 12 weeks ahead Exact sum: 20.7 + 18.7 + 9.1 + 16.9 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · losing its lead · Evidence leans up · 100% evidence 60.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.3/25 · ROCE 14.6% (year to Mar 2026) · Operating margin 17.7% · 100% evidence Valuation 12.3/20 · P/E 47.4× · PEG 1.58 · 100% evidence Relative strength 15.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.8% · Strength vs NIFTY 500 (same reading) 13.2% · 1 year 23.4% · 100% evidence · 9 of 12 weeks ahead Exact sum: 20.9 + 12.3 + 12.3 + 15.4 = 60.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 82% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 50.4% · Profit 19.1% · Operating margin change 1 points · 95% evidence Capital efficiency 12.4/25 · ROCE 12.9% (year to Mar 2026) · Operating margin 23.7% · 76% evidence Valuation 6.7/20 · P/E 55.2× · PEG n/a · 50% evidence Relative strength 19.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 25.3% · Strength vs NIFTY 500 (same reading) 26.5% · 1 year 43.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.9 + 12.4 + 6.7 + 19.1 = 59.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · leader · Evidence leans up · 71% evidence 58.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.0/25 · ROCE 17.2% (year to Mar 2026) · Operating margin 30.1% · 100% evidence Valuation 10.0/20 · P/E 38.6× · PEG n/a · 50% evidence Relative strength 12.0/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 15.4% · 1 year 16% · 25% evidence · 9 of 12 weeks ahead Exact sum: 19.3 + 17 + 10 + 12 = 58.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Revenue 22.8% · Profit 16.8% · Operating margin change -2 points · 100% evidence Capital efficiency 19.7/25 · ROCE 17.4% (year to Mar 2026) · Operating margin 31% · 100% evidence Valuation 11.5/20 · P/E 43.7× · PEG 2.34 · 100% evidence Relative strength 3.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -8% · Strength vs NIFTY 500 (same reading) -6.7% · 1 year -5.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 19.7 + 11.5 + 3 = 51.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · turning · Evidence leans down · 78% evidence 49.0 out of 100 Growth Capital Valuation Relative 12. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans down · 75% evidence 47.9 out of 100 Growth Capital Valuation Relative 13. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · basing · Evidence leans down · 85% evidence 44.5 out of 100 Growth Capital Valuation Relative 14. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 100% evidence 42.4 out of 100 Growth Capital Valuation Relative 15. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 67% evidence 40.2 out of 100 Growth Capital Valuation Relative 16. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · quiet · Evidence leans down · 82% evidence 40.0 out of 100 Growth Capital Valuation Relative 17. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Evidence leans down · 100% evidence 35.8 out of 100 Growth Capital Valuation Relative 18. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 82% evidence 30.6 out of 100 Growth Capital Valuation Relative 19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 75% evidence 24.6 out of 100 Growth Capital Valuation Relative 20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 40% evidence 41.6 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Sakar Healthcare in size? Sakar Healthcare is the 18th largest of 20 Hospitals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Artemis Medicare Services, Indraprastha Medical Corporation, KMC Speciality Hospitals (India) and Dr Agarwals Eye Hospital. Just below it: Shalby and GPT Healthcare. ### Hospitals companies close in size 1. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ₹5,436 crore 2. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) ₹3,282 crore 3. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) ₹3,220 crore 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) ₹2,942 crore 5. Sakar Healthcare Ltd ₹2,246 crore 6. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) ₹1,285 crore 7. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) ₹1,104 crore [All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies) ### Companies close in size in other industries 1. [Pokarna Ltd](https://www.sectoralpha.in/stocks/pokarna-ltd) ₹2,268 crore · Building Material USA 2. [Confidence Petroleum India Ltd](https://www.sectoralpha.in/stocks/confidence-petroleum-india-ltd) ₹2,261 crore · LPG Bottling 3. Sakar Healthcare Ltd ₹2,246 crore 4. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) ₹2,234 crore · Pharma - Formulators 5. [Globus Spirits Ltd](https://www.sectoralpha.in/stocks/globus-spirits-ltd) ₹2,234 crore · Alcoholic Beverages ## What else do people ask about Sakar Healthcare? ### What is Sakar Healthcare's share price today? Sakar Healthcare Ltd's share price is ₹1,009.70, +171.1% over the past year. The whole company is worth ₹2,247 Cr on the market. In the last 52 weeks it traded between ₹372 to ₹1,180; today it is 79% of the way up from the low, 24.6% above its 200-day average (as of 18 November 2026). ### What were Sakar Healthcare's latest quarterly results? Sakar Healthcare Ltd reported revenue of ₹87.0 Cr and net profit of ₹11.0 Cr for the Sep 2026 quarter. Revenue rose 50.0% and profit rose 120.0% compared with a year earlier. Earnings per share were ₹5.08. The operating margin was 27.6%, 8.6 percentage points higher than a year earlier (as of 18 November 2026). ### What is Sakar Healthcare's market cap? Sakar Healthcare Ltd's market capitalisation is ₹2,247 Cr at a share price of ₹1,009.70. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Sakar Healthcare performing? Sakar Healthcare Ltd's share price has been rising for 75 weeks. In its latest quarter, revenue rose 50.0% and profit rose 120.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 18 November 2026). ### Will Sakar Healthcare's share price go up? This page does not forecast Sakar Healthcare Ltd's share price. What it shows instead: the share price is ₹1,009.70, and it has been rising for 75 weeks. Its P/E of 52.4× is higher than 65% of its own last 5 years (as of 18 November 2026). ### Who owns Sakar Healthcare? Promoters own 51.7% of Sakar Healthcare Ltd, foreign institutions 12.3%, domestic institutions 11.9% and the public 24.0% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 1.4 percentage points over 8 quarters (as of 18 November 2026). ### Does Sakar Healthcare have too much debt? No, Sakar Healthcare Ltd has little debt: its debt is 0.22× its equity, and its operating profit is 9 times its interest bill. FY26 borrowings were ₹71.0 Cr against equity of ₹324 Cr. So the returns on this page come from the business, not borrowed money (as of 18 November 2026). ### Where is Sakar Healthcare in its business cycle? Sakar Healthcare Ltd's FY26 operating margin was 27.5%, against a 13-year range of 19.5% to 28.1%. The latest quarter was 27.6%, near the top of its own range. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Sakar Healthcare story? The main question: the share price moved +171.1% in a year while yearly earnings per share moved +71.9%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Sakar Healthcare a stock worth studying right now? What the numbers show: Sakar Healthcare Ltd's share price has risen faster than its earnings: +171.1% in a year, against +71.9% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Sakar Healthcare share price forecast for 2026? What management itself guided: Total revenue growth 35%+ this year and next, Q3 total at ~100Cr quarter. ## Lists - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india This is research, not advice. We’re not SEBI-registered.